Sumitomo Pharma Co (4506.T) Osake Kurssi
Sumitomo Pharma Co Kurssi
Viimeisten 19 vuoden aikana Sumitomo Pharma Con liikevaihto kasvoi 2,9 % vuodessa ja ylsi 453,29 Mrd. JPY:een. Osakekohtainen tulos on kasvanut 8,5 % vuodessa viimeisten 19 vuoden aikana. Sumitomo Pharma Con nettomarginaali 23,6 % on noussut verrattuna 10,1 %:iin muutama vuosi sitten. Nykyhinnalla osinkotuotto on noin 0,37 %. Jakosuhde on noin 22 % tuloksesta. Sumitomo Pharma Con 12 kuukauden konsensustavoitehinta on 2 397,00 JPY, noin yli kurssia 26,6 %. 10 analyytikosta 6 suosittaa ostoa — kokonaiskonsensus on Osta.
Sumitomo Pharma Co osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Sumitomo Pharma Co liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Sumitomo Pharma Co -osakkeesta
The business model of Sumitomo Dainippon Pharma Co Ltd revolves around the development, manufacturing, and commercialization of innovative pharmaceutical products. As a leading Japanese pharmaceutical company, Sumitomo Dainippon Pharma focuses on researching and providing solutions to significant unmet medical needs. By leveraging its expertise in various therapeutic areas, the company aims to improve patients' health and well-being while contributing to society. Sumitomo Dainippon Pharma actively collaborates with partners, both domestically and internationally, to enhance its global presence and deliver effective and safe treatments to a diverse range of patients.
Sumitomo Dainippon Pharma Co Ltd is primarily active in the pharmaceutical industry.
The main competitors of Sumitomo Dainippon Pharma Co Ltd in the market include Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., and Daiichi Sankyo Company, Limited.
Sumitomo Dainippon Pharma Co Ltd is a renowned pharmaceutical company with a rich history and background. Founded in 1897, it has evolved into a global leader in the healthcare industry. Sumitomo Dainippon Pharma focuses on the research, development, and commercialization of innovative pharmaceuticals across therapeutic areas such as neuroscience, oncology, and rare diseases. The company's commitment to improving patient outcomes and addressing unmet medical needs has driven its success. With a strong emphasis on scientific advancements and strategic collaborations, Sumitomo Dainippon Pharma continues to make significant contributions to the global pharmaceutical landscape.
Sumitomo Dainippon Pharma Co Ltd has achieved several significant milestones throughout its history. Notably, the company successfully developed and launched innovative psychiatric medications, such as LATUDA, which has contributed to the treatment of schizophrenia and bipolar disorder. Additionally, Sumitomo Dainippon Pharma Co Ltd expanded its global presence through strategic partnerships and acquisitions, enhancing its research and development capabilities. The company's dedication to advancing healthcare is evident in its commitment to exploring breakthrough therapies and collaborations with leading medical institutions worldwide. These achievements solidify Sumitomo Dainippon Pharma Co Ltd's position as a leading pharmaceutical company focused on improving the lives of patients through innovative treatments and transformative healthcare solutions.
Sumitomo Dainippon Pharma Co Ltd is primarily present in Japan.
Sumitomo Dainippon Pharma Co Ltd is a Japanese company that values innovation, integrity, and dedication to improving patient outcomes. The company's corporate philosophy is rooted in contributing to society through the discovery and development of innovative pharmaceuticals. Sumitomo Dainippon Pharma Co Ltd focuses on research and development to provide effective and safe medical solutions to patients worldwide. With a commitment to continuous growth and improvement, the company strives to enhance the quality of life for individuals and the community as a whole. Sumitomo Dainippon Pharma Co Ltd's corporate philosophy guides its mission to contribute to the health and well-being of society by delivering innovative and reliable pharmaceutical products.
Analyytikot asettavat tällä hetkellä Sumitomo Pharma Co-osakkeelle keskimääräisen tavoitehinnan 2 258,28 JPY (mediaani: 2 397,00 JPY), mikä merkitsee +19,3 % viimeisimpään hintaan verrattuna. Konsensus perustuu 10 analyytikkoarvioon.
10 analyytikkoa arvioi tällä hetkellä Sumitomo Pharma Co-osaketta: 6 suosittaa ostoa, 3 pitoa ja 1 myyntiä.
Nykyisellä valuuttakurssilla Sumitomo Pharma Co-osake noteerataan hintaan 10,77 EUR (1 893,00 JPY).
Sumitomo Pharma Co-osake (4506.T) on listattuna 5 pörssissä, muun muassa: Tokio (JPX) (4506.T), Frankfurt (DPM.F), München (DPM.MU), Düsseldorf (DPM.DU).
Sumitomo Dainippon Pharma Co Ltd is a well-known Japanese pharmaceutical company that has been in existence since 1896 and is headquartered in Osaka. The company operates in many fields, including mental health, cancer, diabetes, and psychiatric disorders. The main business of Sumitomo Dainippon Pharma is drug development, manufacturing, and marketing. The company offers a wide range of products in various medical specialties, including flagship products such as "Cablivi," an innovative medication for the treatment of thrombotic thrombocytopenic purpura (TTP), and "Latuda," a medication used for the treatment of schizophrenia and bipolar disorders. Sumitomo Dainippon Pharma is also involved in the generic industry. Generics are imitations of brand-name drugs and usually have the same active ingredient content as the original product but are less expensive. The company offers a wide range of generics to meet the needs of patients worldwide. The company also covers the manufacturing and sale of diagnostic systems for clinical practice. The company also conducts preclinical and clinical trials for new drugs, including Holland chamber studies and phase I-IV studies for new drug developments to evaluate their safety and efficacy. In addition, Sumitomo Dainippon Pharma has integrated medical technology, also known as medical devices. The company invests in creative research to develop innovative medical devices that improve the quality of patients' health worldwide. These include diagnostic devices, medical devices, insulin cooling devices, and other medical devices. The company is also involved in the production and sale of cosmetic products, mainly including anti-aging products, skincare products, and makeup products. Several mergers and acquisitions have helped Sumitomo Dainippon Pharma expand its business into various areas in recent years. In 2010, the company expanded into the field of cancer research through the acquisition of Boston Biomedical. A year later, the company acquired Irish company Shionogi & Co Ltd. and entered the business of pharmaceuticals for psychiatric disorders. In 2018, Sumitomo Dainippon Pharma acquired Latin American company Companhia Brasileira de Distribuição Remedios and Midatech Pharma PLC, a company specialized in the development of drugs for rare and life-threatening diseases. Overall, the business model of Sumitomo Dainippon Pharma is very comprehensive and aims to provide a wide range of medical products and services to improve patients' lives. The company is committed to achieving growth and expansion through innovative research and development of new products, as well as through acquisitions and mergers.
liikevaihto Sumitomo Pharma Co on 453,29 Mrd. JPY. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
voitto Sumitomo Pharma Co on 106,87 Mrd. JPY. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Sumitomo Pharma Co:n hinta-voitto-suhde (P/E) on tällä hetkellä 7,72. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Sumitomo Pharma Co-osakkeen arvostusta.
Sumitomo Pharma Co:n hinta-myynti-suhde (P/S) on tällä hetkellä 1,82. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Sumitomo Pharma Co-osakkeen arvostuskennuslukuna.
Sumitomo Pharma Co:n Eulpool-laatuscore on 4/10.
Sumitomo Pharma Co:n ISIN on JP3495000006. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Sumitomo Pharma Co:n WKN on 858257. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Sumitomo Pharma Co:n ticker on 4506.T. Tämä pörssinoteeraus käytetään Sumitomo Pharma Co-osakkeiden kauppaan pörssissä.
Sumitomo Pharma Co osake
Sumitomo Pharma Co vertaisryhmä
Sumitomo Pharma Co Ticker
Sumitomo Pharma Co FIGI
Kaikki tunnusluvut ja syvällinen analyysi Sumitomo Pharma Co:sta
Meidän osakeanalyysimme Sumitomo Pharma Co-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Sumitomo Pharma Co:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: